nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—Psychomotor skills impaired—Varenicline—nicotine dependence	0.0743	0.0955	CcSEcCtD
Tacrolimus—ORM1—saliva—nicotine dependence	0.0525	0.26	CbGeAlD
Tacrolimus—Rhinitis allergic—Varenicline—nicotine dependence	0.0273	0.0351	CcSEcCtD
Tacrolimus—ABCA5—midbrain—nicotine dependence	0.0235	0.117	CbGeAlD
Tacrolimus—Enterocolitis—Varenicline—nicotine dependence	0.0223	0.0287	CcSEcCtD
Tacrolimus—PPP3CA—cardiovascular system—nicotine dependence	0.0203	0.101	CbGeAlD
Tacrolimus—PPP3CA—midbrain—nicotine dependence	0.0159	0.0787	CbGeAlD
Tacrolimus—MTOR—cardiovascular system—nicotine dependence	0.015	0.0745	CbGeAlD
Tacrolimus—ABCA5—brain—nicotine dependence	0.0148	0.0732	CbGeAlD
Tacrolimus—Depressed mood—Varenicline—nicotine dependence	0.0138	0.0178	CcSEcCtD
Tacrolimus—FKBP1A—cardiovascular system—nicotine dependence	0.0135	0.067	CbGeAlD
Tacrolimus—Pancreatitis acute—Varenicline—nicotine dependence	0.0134	0.0172	CcSEcCtD
Tacrolimus—Aphthous stomatitis—Varenicline—nicotine dependence	0.0132	0.017	CcSEcCtD
Tacrolimus—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0126	0.0162	CcSEcCtD
Tacrolimus—Osteoporosis—Varenicline—nicotine dependence	0.011	0.0142	CcSEcCtD
Tacrolimus—Gastric ulcer—Varenicline—nicotine dependence	0.0107	0.0137	CcSEcCtD
Tacrolimus—FKBP1A—midbrain—nicotine dependence	0.0106	0.0523	CbGeAlD
Tacrolimus—PPP3CA—brain—nicotine dependence	0.00998	0.0495	CbGeAlD
Tacrolimus—Electrocardiogram abnormal—Varenicline—nicotine dependence	0.00945	0.0121	CcSEcCtD
Tacrolimus—Cyst—Varenicline—nicotine dependence	0.00926	0.0119	CcSEcCtD
Tacrolimus—Intestinal obstruction—Varenicline—nicotine dependence	0.00908	0.0117	CcSEcCtD
Tacrolimus—Thrombosis—Varenicline—nicotine dependence	0.00875	0.0112	CcSEcCtD
Tacrolimus—Nystagmus—Varenicline—nicotine dependence	0.00867	0.0111	CcSEcCtD
Tacrolimus—Hyperlipidaemia—Varenicline—nicotine dependence	0.00859	0.011	CcSEcCtD
Tacrolimus—Glycosuria—Varenicline—nicotine dependence	0.00764	0.00982	CcSEcCtD
Tacrolimus—Endocrine disorder—Varenicline—nicotine dependence	0.00747	0.0096	CcSEcCtD
Tacrolimus—MTOR—brain—nicotine dependence	0.00737	0.0365	CbGeAlD
Tacrolimus—Acne—Varenicline—nicotine dependence	0.00736	0.00946	CcSEcCtD
Tacrolimus—Chest discomfort—Varenicline—nicotine dependence	0.007	0.00899	CcSEcCtD
Tacrolimus—Accidental injury—Varenicline—nicotine dependence	0.007	0.00899	CcSEcCtD
Tacrolimus—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00685	0.00881	CcSEcCtD
Tacrolimus—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00685	0.00881	CcSEcCtD
Tacrolimus—Thinking abnormal—Varenicline—nicotine dependence	0.00676	0.00869	CcSEcCtD
Tacrolimus—Nocturia—Varenicline—nicotine dependence	0.00667	0.00858	CcSEcCtD
Tacrolimus—FKBP1A—brain—nicotine dependence	0.00663	0.0329	CbGeAlD
Tacrolimus—Leukocytosis—Varenicline—nicotine dependence	0.00659	0.00847	CcSEcCtD
Tacrolimus—Dysarthria—Varenicline—nicotine dependence	0.00655	0.00841	CcSEcCtD
Tacrolimus—Coordination abnormal—Varenicline—nicotine dependence	0.0063	0.0081	CcSEcCtD
Tacrolimus—Abnormal dreams—Varenicline—nicotine dependence	0.00612	0.00786	CcSEcCtD
Tacrolimus—Hyperkalaemia—Varenicline—nicotine dependence	0.00608	0.00782	CcSEcCtD
Tacrolimus—Influenza like illness—Varenicline—nicotine dependence	0.00601	0.00773	CcSEcCtD
Tacrolimus—Nightmare—Varenicline—nicotine dependence	0.00598	0.00768	CcSEcCtD
Tacrolimus—Photophobia—Varenicline—nicotine dependence	0.00581	0.00747	CcSEcCtD
Tacrolimus—Dry eye—Varenicline—nicotine dependence	0.00572	0.00735	CcSEcCtD
Tacrolimus—Oesophagitis—Varenicline—nicotine dependence	0.00566	0.00727	CcSEcCtD
Tacrolimus—Mouth ulceration—Varenicline—nicotine dependence	0.0056	0.0072	CcSEcCtD
Tacrolimus—Hypertonia—Varenicline—nicotine dependence	0.00543	0.00698	CcSEcCtD
Tacrolimus—Mental disability—Varenicline—nicotine dependence	0.00537	0.00691	CcSEcCtD
Tacrolimus—Lymphadenopathy—Varenicline—nicotine dependence	0.00527	0.00677	CcSEcCtD
Tacrolimus—Diabetes mellitus—Varenicline—nicotine dependence	0.00517	0.00664	CcSEcCtD
Tacrolimus—Disorientation—Varenicline—nicotine dependence	0.00502	0.00646	CcSEcCtD
Tacrolimus—Deafness—Varenicline—nicotine dependence	0.00502	0.00646	CcSEcCtD
Tacrolimus—Eczema—Varenicline—nicotine dependence	0.005	0.00643	CcSEcCtD
Tacrolimus—Eye pain—Varenicline—nicotine dependence	0.00498	0.0064	CcSEcCtD
Tacrolimus—Injury—Varenicline—nicotine dependence	0.00489	0.00628	CcSEcCtD
Tacrolimus—Renal failure acute—Varenicline—nicotine dependence	0.00487	0.00626	CcSEcCtD
Tacrolimus—Hot flush—Varenicline—nicotine dependence	0.0048	0.00618	CcSEcCtD
Tacrolimus—Amnesia—Varenicline—nicotine dependence	0.00478	0.00615	CcSEcCtD
Tacrolimus—Increased appetite—Varenicline—nicotine dependence	0.00478	0.00615	CcSEcCtD
Tacrolimus—Menopausal symptoms—Varenicline—nicotine dependence	0.00476	0.00612	CcSEcCtD
Tacrolimus—Atrial fibrillation—Varenicline—nicotine dependence	0.00474	0.0061	CcSEcCtD
Tacrolimus—Thirst—Varenicline—nicotine dependence	0.00472	0.00607	CcSEcCtD
Tacrolimus—Arthritis—Varenicline—nicotine dependence	0.00462	0.00594	CcSEcCtD
Tacrolimus—Hypoglycaemia—Varenicline—nicotine dependence	0.0046	0.00592	CcSEcCtD
Tacrolimus—ALB—brain—nicotine dependence	0.00455	0.0226	CbGeAlD
Tacrolimus—Osteoarthritis—Varenicline—nicotine dependence	0.00449	0.00578	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00449	0.00578	CcSEcCtD
Tacrolimus—Affect lability—Varenicline—nicotine dependence	0.00442	0.00569	CcSEcCtD
Tacrolimus—Migraine—Varenicline—nicotine dependence	0.00442	0.00569	CcSEcCtD
Tacrolimus—Psychotic disorder—Varenicline—nicotine dependence	0.00439	0.00564	CcSEcCtD
Tacrolimus—Urinary retention—Varenicline—nicotine dependence	0.00427	0.00549	CcSEcCtD
Tacrolimus—Mood swings—Varenicline—nicotine dependence	0.00426	0.00547	CcSEcCtD
Tacrolimus—Liver function test abnormal—Varenicline—nicotine dependence	0.00415	0.00533	CcSEcCtD
Tacrolimus—Dry skin—Varenicline—nicotine dependence	0.00412	0.0053	CcSEcCtD
Tacrolimus—Hypokalaemia—Varenicline—nicotine dependence	0.00409	0.00526	CcSEcCtD
Tacrolimus—Breast disorder—Varenicline—nicotine dependence	0.00406	0.00522	CcSEcCtD
Tacrolimus—Cramp muscle—Varenicline—nicotine dependence	0.00405	0.0052	CcSEcCtD
Tacrolimus—Gastritis—Varenicline—nicotine dependence	0.00398	0.00511	CcSEcCtD
Tacrolimus—Abdominal distension—Varenicline—nicotine dependence	0.00391	0.00503	CcSEcCtD
Tacrolimus—Asthma—Varenicline—nicotine dependence	0.00388	0.00499	CcSEcCtD
Tacrolimus—Dysphagia—Varenicline—nicotine dependence	0.00388	0.00499	CcSEcCtD
Tacrolimus—Angina pectoris—Varenicline—nicotine dependence	0.00378	0.00486	CcSEcCtD
Tacrolimus—Bronchitis—Varenicline—nicotine dependence	0.00374	0.0048	CcSEcCtD
Tacrolimus—Pollakiuria—Varenicline—nicotine dependence	0.00359	0.00461	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Varenicline—nicotine dependence	0.00355	0.00456	CcSEcCtD
Tacrolimus—Weight increased—Varenicline—nicotine dependence	0.00353	0.00454	CcSEcCtD
Tacrolimus—Hyperglycaemia—Varenicline—nicotine dependence	0.0035	0.0045	CcSEcCtD
Tacrolimus—Infestation NOS—Varenicline—nicotine dependence	0.00346	0.00445	CcSEcCtD
Tacrolimus—Infestation—Varenicline—nicotine dependence	0.00346	0.00445	CcSEcCtD
Tacrolimus—Depression—Varenicline—nicotine dependence	0.00345	0.00444	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00343	0.00441	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Varenicline—nicotine dependence	0.00341	0.00439	CcSEcCtD
Tacrolimus—Myocardial infarction—Varenicline—nicotine dependence	0.00339	0.00436	CcSEcCtD
Tacrolimus—Stomatitis—Varenicline—nicotine dependence	0.00338	0.00434	CcSEcCtD
Tacrolimus—Conjunctivitis—Varenicline—nicotine dependence	0.00337	0.00433	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Varenicline—nicotine dependence	0.00328	0.00421	CcSEcCtD
Tacrolimus—Epistaxis—Varenicline—nicotine dependence	0.00327	0.0042	CcSEcCtD
Tacrolimus—Sinusitis—Varenicline—nicotine dependence	0.00325	0.00418	CcSEcCtD
Tacrolimus—Bradycardia—Varenicline—nicotine dependence	0.00316	0.00407	CcSEcCtD
Tacrolimus—ABCB1—cardiovascular system—nicotine dependence	0.00313	0.0155	CbGeAlD
Tacrolimus—Hypoaesthesia—Varenicline—nicotine dependence	0.00309	0.00398	CcSEcCtD
Tacrolimus—Hallucination—Varenicline—nicotine dependence	0.00309	0.00398	CcSEcCtD
Tacrolimus—Urinary tract disorder—Varenicline—nicotine dependence	0.00307	0.00395	CcSEcCtD
Tacrolimus—Oedema peripheral—Varenicline—nicotine dependence	0.00306	0.00394	CcSEcCtD
Tacrolimus—Connective tissue disorder—Varenicline—nicotine dependence	0.00306	0.00393	CcSEcCtD
Tacrolimus—Urethral disorder—Varenicline—nicotine dependence	0.00305	0.00392	CcSEcCtD
Tacrolimus—Visual impairment—Varenicline—nicotine dependence	0.003	0.00385	CcSEcCtD
Tacrolimus—Erythema multiforme—Varenicline—nicotine dependence	0.00294	0.00378	CcSEcCtD
Tacrolimus—Eye disorder—Varenicline—nicotine dependence	0.00291	0.00373	CcSEcCtD
Tacrolimus—Tinnitus—Varenicline—nicotine dependence	0.0029	0.00373	CcSEcCtD
Tacrolimus—Cardiac disorder—Varenicline—nicotine dependence	0.00289	0.00371	CcSEcCtD
Tacrolimus—Angiopathy—Varenicline—nicotine dependence	0.00282	0.00363	CcSEcCtD
Tacrolimus—Immune system disorder—Varenicline—nicotine dependence	0.00281	0.00361	CcSEcCtD
Tacrolimus—Mediastinal disorder—Varenicline—nicotine dependence	0.0028	0.0036	CcSEcCtD
Tacrolimus—Chills—Varenicline—nicotine dependence	0.00279	0.00359	CcSEcCtD
Tacrolimus—Arrhythmia—Varenicline—nicotine dependence	0.00278	0.00357	CcSEcCtD
Tacrolimus—Mental disorder—Varenicline—nicotine dependence	0.00272	0.0035	CcSEcCtD
Tacrolimus—Erythema—Varenicline—nicotine dependence	0.00271	0.00348	CcSEcCtD
Tacrolimus—Malnutrition—Varenicline—nicotine dependence	0.00271	0.00348	CcSEcCtD
Tacrolimus—Flatulence—Varenicline—nicotine dependence	0.00267	0.00343	CcSEcCtD
Tacrolimus—Dysgeusia—Varenicline—nicotine dependence	0.00265	0.00341	CcSEcCtD
Tacrolimus—Back pain—Varenicline—nicotine dependence	0.00262	0.00337	CcSEcCtD
Tacrolimus—Muscle spasms—Varenicline—nicotine dependence	0.0026	0.00334	CcSEcCtD
Tacrolimus—Vision blurred—Varenicline—nicotine dependence	0.00255	0.00328	CcSEcCtD
Tacrolimus—Tremor—Varenicline—nicotine dependence	0.00254	0.00326	CcSEcCtD
Tacrolimus—Ill-defined disorder—Varenicline—nicotine dependence	0.00251	0.00323	CcSEcCtD
Tacrolimus—Anaemia—Varenicline—nicotine dependence	0.0025	0.00322	CcSEcCtD
Tacrolimus—Agitation—Varenicline—nicotine dependence	0.00249	0.0032	CcSEcCtD
Tacrolimus—ABCB1—midbrain—nicotine dependence	0.00244	0.0121	CbGeAlD
Tacrolimus—Malaise—Varenicline—nicotine dependence	0.00244	0.00314	CcSEcCtD
Tacrolimus—Vertigo—Varenicline—nicotine dependence	0.00243	0.00313	CcSEcCtD
Tacrolimus—Syncope—Varenicline—nicotine dependence	0.00243	0.00312	CcSEcCtD
Tacrolimus—Palpitations—Varenicline—nicotine dependence	0.00239	0.00307	CcSEcCtD
Tacrolimus—Loss of consciousness—Varenicline—nicotine dependence	0.00238	0.00306	CcSEcCtD
Tacrolimus—Cough—Varenicline—nicotine dependence	0.00236	0.00304	CcSEcCtD
Tacrolimus—Convulsion—Varenicline—nicotine dependence	0.00234	0.00301	CcSEcCtD
Tacrolimus—Hypertension—Varenicline—nicotine dependence	0.00234	0.003	CcSEcCtD
Tacrolimus—Arthralgia—Varenicline—nicotine dependence	0.0023	0.00296	CcSEcCtD
Tacrolimus—Chest pain—Varenicline—nicotine dependence	0.0023	0.00296	CcSEcCtD
Tacrolimus—Myalgia—Varenicline—nicotine dependence	0.0023	0.00296	CcSEcCtD
Tacrolimus—Anxiety—Varenicline—nicotine dependence	0.0023	0.00295	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00229	0.00294	CcSEcCtD
Tacrolimus—Discomfort—Varenicline—nicotine dependence	0.00228	0.00293	CcSEcCtD
Tacrolimus—Dry mouth—Varenicline—nicotine dependence	0.00225	0.0029	CcSEcCtD
Tacrolimus—Oedema—Varenicline—nicotine dependence	0.00221	0.00284	CcSEcCtD
Tacrolimus—Infection—Varenicline—nicotine dependence	0.00219	0.00282	CcSEcCtD
Tacrolimus—Shock—Varenicline—nicotine dependence	0.00217	0.00279	CcSEcCtD
Tacrolimus—Nervous system disorder—Varenicline—nicotine dependence	0.00217	0.00278	CcSEcCtD
Tacrolimus—Thrombocytopenia—Varenicline—nicotine dependence	0.00216	0.00278	CcSEcCtD
Tacrolimus—Tachycardia—Varenicline—nicotine dependence	0.00216	0.00277	CcSEcCtD
Tacrolimus—Skin disorder—Varenicline—nicotine dependence	0.00215	0.00276	CcSEcCtD
Tacrolimus—Hyperhidrosis—Varenicline—nicotine dependence	0.00214	0.00274	CcSEcCtD
Tacrolimus—Anorexia—Varenicline—nicotine dependence	0.00211	0.00271	CcSEcCtD
Tacrolimus—Hypotension—Varenicline—nicotine dependence	0.00206	0.00265	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00201	0.00259	CcSEcCtD
Tacrolimus—Insomnia—Varenicline—nicotine dependence	0.002	0.00257	CcSEcCtD
Tacrolimus—Dyspnoea—Varenicline—nicotine dependence	0.00197	0.00253	CcSEcCtD
Tacrolimus—Somnolence—Varenicline—nicotine dependence	0.00196	0.00252	CcSEcCtD
Tacrolimus—Dyspepsia—Varenicline—nicotine dependence	0.00194	0.0025	CcSEcCtD
Tacrolimus—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.00193	0.0946	CbGpPWpGaD
Tacrolimus—Decreased appetite—Varenicline—nicotine dependence	0.00192	0.00247	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00191	0.00245	CcSEcCtD
Tacrolimus—Fatigue—Varenicline—nicotine dependence	0.0019	0.00245	CcSEcCtD
Tacrolimus—Constipation—Varenicline—nicotine dependence	0.00189	0.00243	CcSEcCtD
Tacrolimus—Pain—Varenicline—nicotine dependence	0.00189	0.00243	CcSEcCtD
Tacrolimus—Feeling abnormal—Varenicline—nicotine dependence	0.00182	0.00234	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Varenicline—nicotine dependence	0.00181	0.00232	CcSEcCtD
Tacrolimus—Urticaria—Varenicline—nicotine dependence	0.00175	0.00226	CcSEcCtD
Tacrolimus—Abdominal pain—Varenicline—nicotine dependence	0.00175	0.00224	CcSEcCtD
Tacrolimus—Body temperature increased—Varenicline—nicotine dependence	0.00175	0.00224	CcSEcCtD
Tacrolimus—Hypersensitivity—Varenicline—nicotine dependence	0.00163	0.00209	CcSEcCtD
Tacrolimus—Asthenia—Varenicline—nicotine dependence	0.00158	0.00204	CcSEcCtD
Tacrolimus—Pruritus—Varenicline—nicotine dependence	0.00156	0.00201	CcSEcCtD
Tacrolimus—ABCB1—brain—nicotine dependence	0.00153	0.0076	CbGeAlD
Tacrolimus—Diarrhoea—Varenicline—nicotine dependence	0.00151	0.00194	CcSEcCtD
Tacrolimus—Dizziness—Varenicline—nicotine dependence	0.00146	0.00188	CcSEcCtD
Tacrolimus—Vomiting—Varenicline—nicotine dependence	0.0014	0.00181	CcSEcCtD
Tacrolimus—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00139	0.0684	CbGpPWpGaD
Tacrolimus—Rash—Varenicline—nicotine dependence	0.00139	0.00179	CcSEcCtD
Tacrolimus—Dermatitis—Varenicline—nicotine dependence	0.00139	0.00179	CcSEcCtD
Tacrolimus—Headache—Varenicline—nicotine dependence	0.00138	0.00178	CcSEcCtD
Tacrolimus—Nausea—Varenicline—nicotine dependence	0.00131	0.00169	CcSEcCtD
Tacrolimus—PPP3CA—Opioid Signalling—OPRM1—nicotine dependence	0.0012	0.0588	CbGpPWpGaD
Tacrolimus—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0008	0.0393	CbGpPWpGaD
Tacrolimus—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00079	0.0388	CbGpPWpGaD
Tacrolimus—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000649	0.0319	CbGpPWpGaD
Tacrolimus—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.000648	0.0318	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—OPRM1—nicotine dependence	0.000646	0.0317	CbGpPWpGaD
Tacrolimus—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000578	0.0284	CbGpPWpGaD
Tacrolimus—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000571	0.028	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—WASF2—nicotine dependence	0.000491	0.0241	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.000484	0.0238	CbGpPWpGaD
Tacrolimus—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000469	0.023	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.000464	0.0228	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—WASF2—nicotine dependence	0.000457	0.0224	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—WASF1—nicotine dependence	0.000438	0.0215	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—TAS2R16—nicotine dependence	0.000376	0.0185	CbGpPWpGaD
Tacrolimus—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000366	0.018	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—FGD1—nicotine dependence	0.000354	0.0174	CbGpPWpGaD
Tacrolimus—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.000345	0.0169	CbGpPWpGaD
Tacrolimus—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00034	0.0167	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—FGD1—nicotine dependence	0.000295	0.0145	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—WASF2—nicotine dependence	0.000288	0.0142	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—WASF1—nicotine dependence	0.000276	0.0136	CbGpPWpGaD
Tacrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000269	0.0132	CbGpPWpGaD
Tacrolimus—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000265	0.013	CbGpPWpGaD
Tacrolimus—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000264	0.013	CbGpPWpGaD
Tacrolimus—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000249	0.0122	CbGpPWpGaD
Tacrolimus—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000246	0.0121	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TAS2R16—nicotine dependence	0.000222	0.0109	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKR1B10—nicotine dependence	0.00022	0.0108	CbGpPWpGaD
Tacrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000218	0.0107	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—FGD1—nicotine dependence	0.000174	0.00856	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000172	0.00846	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKR1B10—nicotine dependence	0.000171	0.00837	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—WASF2—nicotine dependence	0.000168	0.00824	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—WASF1—nicotine dependence	0.000161	0.0079	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—OPRM1—nicotine dependence	0.000159	0.00779	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKR1B10—nicotine dependence	0.000154	0.00756	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FGD1—nicotine dependence	0.000135	0.00664	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—WASF2—nicotine dependence	0.000126	0.00617	CbGpPWpGaD
Tacrolimus—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000123	0.00603	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—WASF1—nicotine dependence	0.00012	0.00592	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000119	0.00586	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000116	0.00569	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—DRD2—nicotine dependence	0.000115	0.00563	CbGpPWpGaD
Tacrolimus—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000114	0.00561	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—WASF2—nicotine dependence	0.000109	0.00533	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—WASF1—nicotine dependence	0.000104	0.00511	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TAS2R16—nicotine dependence	9.69e-05	0.00476	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKR1B10—nicotine dependence	9.59e-05	0.00471	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—OPRM1—nicotine dependence	9.37e-05	0.0046	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—WASF2—nicotine dependence	8.41e-05	0.00413	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—WASF1—nicotine dependence	8.07e-05	0.00396	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—GABRA4—nicotine dependence	7.83e-05	0.00385	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGD1—nicotine dependence	7.6e-05	0.00373	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—WASF2—nicotine dependence	7.32e-05	0.00359	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—OPRM1—nicotine dependence	7.26e-05	0.00357	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—WASF1—nicotine dependence	7.02e-05	0.00345	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	6.86e-05	0.00337	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—DRD2—nicotine dependence	6.77e-05	0.00333	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKR1B10—nicotine dependence	6.72e-05	0.0033	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP2A7—nicotine dependence	5.89e-05	0.00289	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—DRD2—nicotine dependence	5.25e-05	0.00258	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—WASF2—nicotine dependence	4.73e-05	0.00232	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—WASF1—nicotine dependence	4.54e-05	0.00223	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP2A7—nicotine dependence	4.26e-05	0.00209	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—OPRM1—nicotine dependence	4.08e-05	0.00201	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP2A7—nicotine dependence	3.67e-05	0.0018	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP2A7—nicotine dependence	3.21e-05	0.00158	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—DRD2—nicotine dependence	2.95e-05	0.00145	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2A7—nicotine dependence	1.98e-05	0.000973	CbGpPWpGaD
